Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen.
Kai HuangImke SchatkaJulian M M RogaschRandall L LindquistMaria De SantisBarbara ErberPiotr RadojewskiWinfried BrennerHolger AmthauerPublished in: Annals of nuclear medicine (2020)
The presented predictive score allowed a pre-therapeutic estimate of the expected response to 2 cycles of RLT. As our study was retrospective, prospective trials are needed for validation.